Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
With the 500K shares of Baudax that we bought recently, I think that signals we will merge with them, and then the combined company can address the issues necessary to regain Nasdaq compliance, and avoid bankruptcy altogether.
I wish I had even 10% of the shares you will have, so I'm very happy for you.
In the event they somehow will still see an advantage in filing bankruptcy (I can't see it if they recall the shares), then take a breadth. They previously exited Ch 11 with the share structure intact.
Those CMML results are practically miraculous. The doctors and nurses who have spent their entire careers attending to CMML patients would probably disagree with saying "practically" miraculous. Just incredible, and I hope the FDA will consider the CMML safety and efficacy of lenz as they decide on our covid EUA approval.
The only indication I have that management wants to stay away from bankruptcy was the data that showed 110M shares more in the float, than what the company had issued, and management seemed to have control of those shares. I don't think management would risk a forced Ch7, vs Ch11.
But I don't know, DTG. You have to consider that last 8-K (without seeing an 8-Jay, which is what I see). But I have much more to gain, than to lose.
In addition, a bankruptcy (Ch11) was in the playbook we used the first time, so it really is a possibility.
I think a share recall will be announced, and then a 5:1 forward stock split will be declared.
https://valueofstocks.com/2022/06/01/share-recall/
And then I hope we don't hear another peep about a bankruptcy.
I also hope we don't give up 40% of our stock to a combined business we could form with Baudax. I just don't see enough value there for them to end up with 22% of our stock (with us holding the other 18% as part of the combined business). But, that value COULD be there, when TeraImmune is considered. I just don't know. I also don't know how they were trading in the $30 range in the last year.
For that matter, a merger with Baudax could even be bigger than just as part of a combined business, assuming we aren't just looking for a partnership, which I initially thought. I'll be glad to see the 10-Q, and maybe get some guidance.
Is this the type of safety and efficacy data that the FDA wanted to see for authorizing lenz for covid (besides our ACTIV-5 data which appears comparable to the data used to authorize Gohibic for late stage patients)?
"In the open label, nonrandomized PREACH-M trial, 72 patients with CMML were enrolled...
Among patients in the lenzilumab arm there was a 5.1-fold decrease in monocyte counts (P = .03) and 2.4-fold decrease in blast counts (P = .04) at 12 months of follow-up.
In addition there was a trend toward increased platelet counts over baseline at 12 months, a significant increase in blood hemoglobin concentration (P = .024), a significant reduction in spleen size (P = .03) and a trend toward lower levels of the inflammatory marker C-reactive protein...
Thomas told Medscape that the investigators have been "pleasantly surprised” at how well patients tolerated the monoclonal antibody.
"We haven't had any infusion reactions, we haven't had any pulmonary alveolar proteinosis, we haven't had any fevers from the infusion, from the antibody,” he said."
Each parameter (blood monocytes, bone marrow blast percentage, platelet count, blood hemoglobin concentration, and spleen size) has exhibited a durable return to normal or near normal values, with statistical significance. Two of the ten participants have been in the trial for 18 months, the longest of any participants, and exhibit lasting improvement. No participants have relapsed. One participant is now a candidate for stem cell transplantation, which may lead to a potential cure in that patient."
Additionally, there has been a notable increase in the number of Chinese nationals illegally crossing our southern border. A Chinese company was found to have opened an illegal biotech operation in California, which possessed several lethal viruses stored on site, and hundreds of mice bio-engineered to catch and carry covid. Does the FDA really want to see all of our lenz sold overseas?
In addition, nearly a "...dozen Russian and Chinese ships that sailed near Alaska's Aleutian Islands last week as part of a joint exercise -- leading the U.S. to deploy warships and aircraft to monitor the formation -- are now moving away from the region, according to two American officials."
https://abcnews.go.com/Politics/dozen-russian-chinese-ships-now-moving-alaska-officials/story?id=102074925
If the US government hasn't approached/ordered Humanigen to produce a stockpile of lenz for national defense, how much more provocation is it going to take to get them to admit that we have no Medical Countermeasures available to prevent or treat our population against a new wave of covid, especially if it is bio-engineered as a weapon?
The last options granted for them are out of the money at $0.38 (or, free shares, according to Yooo).
https://www.sec.gov/Archives/edgar/data/1293310/000121465922009390/xslF345X03/marketforms-56758.xml
https://www.sec.gov/Archives/edgar/data/1293310/000121465922009392/xslF345X03/marketforms-56760.xml
https://www.sec.gov/Archives/edgar/data/1293310/000121465922009384/xslF345X03/marketforms-56751.xml
Those shares can be made available for sale by the company. No major benefit...at the current market price.
I was absolutely thrilled to get the aGvHD trial news from Humanigen this morning...about 3 hours after getting a response from the ASCENT trial coordinator informing me that, "...any correspondence will be coming from Humanigen directly."
Ok, so the trial is getting started later than I expected. But it's another sign of forward progress being made by Humanigen.
And...to me, this is one of the most important developments I could have heard about. I say that because of lenzilumab's AMAZING progress in the CMML trial, where numerous conditions were restored to normal, or near normal levels in the patients, who could go on to become cured of cancer, following stem cell transplantation, where lenz could also prevent associated aGvHD.
Cured of cancer!
OUTSTANDING!!
https://s28.q4cdn.com/539885110/files/doc_news/Humanigen-Announces-First-Participant-Dosed-in-RATinG-Trial-of-Lenzilumab-for-Early-Treatment-of-Acute-Graft-Versus-Host-Disease-Foll-SP9A5.pdf
"Each parameter (blood monocytes, bone marrow blast percentage, platelet count, blood hemoglobin concentration, and spleen size) has exhibited a durable return to normal or near normal values, with statistical significance. Two of the ten participants have been in the trial for 18 months, the longest of any participants, and exhibit lasting improvement. No participants have relapsed. One participant is now a candidate for stem cell transplantation, which may lead to a potential cure in that patient."
https://medicalresearch.com/cancer-_-oncology/preach-m-trial-humanigen-study-evaluates-lenzilumab-and-azacitidine-for-cmml/
I think you're right, sosjtb. We've already had enough lenz tossed into a dumpster, 300K vials, as I recall.
I think only one of what I expect are two mergers are ready to be executed now, and that would be with Baudax. PCI Pharma may have to wait, if they want to be assured of a Nasdaq listing (and that's assuming that they are being considered at all).
I think we are in the middle of controlled chaos. We've seen it before, in several different aspects: the reduction in headcount, the inability to execute a planned strategic alternative, the lack of cash, delisting, board resignations. All stuff from an old playbook.
If we continue true to form, we should be announcing a recall of our loaned shares. That was important in the old playbook, but it will be even MORE IMPORTANT in the new PAYbook.
The old playbook allowed us to survive.
The new PAYbook will allow us to succeed.
We still need to complete the transition. Previously, we had promising drugs, but no approvals. Now, those drugs have been tested and proven in clinical trials, but we are still awaiting approvals. I don't really know how the aGvHD trial is going. I've contacted them, but have not had a response. However, I think we are a little late with seeing interim results. CMML looks fantastic, from what we have seen. Seeing more would be better, but I don't think it is necessary to be awarded a tentative approval. The covid results are unmatched, but to ensure Pfizer's revenue, we may have to hope that MHRA will finally make an independent approval decision, separate from the FDA. I think the EU would be accommodating, but I don't know if Cenexi will provide the infrastructure for us, or if we need/want them to. I just have a feeling that we are least prepared, for where we could be most wanted.
The biggest change has been covid. And that is a real game-changer, not even dreamed of in the old playbook. That could eliminate our need for a major new investor. If this little company can get into the end zone, we could be looking at $15B or more in revenue. WOW!!!
I have replied on Twitter to Geert's video message about the danger posed to twice re-infected covid patients in the next wave of the virus.
Here's a link to his video.
https://rumble.com/v2zt5n0-assuming-my-predictions-are-correct-who-will-be-at-risk-and-who-will-not.html
And here is the reply I sent to him on Twitter.
"Regarding options for twice-infected covid patients, Humanigen has developed a lenzilumab/w/traditional vaccine/w/ anti-viral cocktail, and polyclonal antibodies, that could prove to be an effective preventative or treatment for those patients. Please evaluate this option."
I couldn't say more due to space limitations for Twitter replies. If he replies to me, I will send him links to additional data, unless Geert asks management for additional information.
It took me awhile to realize that the OS was a calculated number, but that the float was a given number. I'm glad you seem to recall seeing the data!
In terms of financial reward, people who are just taking a position will gain the most. My average price is now down to $0.51 per share, and that is down substantially. But I have a very small account. I wish I had as many shares when I was selling in the $27-$29 range as I have now. But the thing is, I WILL have many more shares the NEXT time we trade through that price range.
And to be honest, my patience is worn thin.
I hope the guiding force for management's course is determined by regulatory approval and the corporate actions they can then take to maximize that financial potential.
I think people who have the most to gain from realizing our potential (current and future shareholders), have less understanding of what that means, than do the people who have the most to lose by our success (Big Pharma in these treatment fields, our competitors, and our enemies). The lenz method of action is the most effective, most broad-based, and the safest there is, and it is ours alone. That's the cornerstone that will not falter.
The OS and float numbers I indicated were only on this site, and only for a couple of days.
GTSY again, DTGoody.
Certain data, indicating a short position here, has once again gone dark. We longer see the OS and float reported here in the Ihub financial section. And ShortVolumes.com once again has quit reporting short volume on HGEN since July 25th.
http://shortvolumes.com/?t=HGEN
I maintain what I have been saying for quite some time, that the company owns every share they have issued. Evidence of that was demonstrated by the float changing to a level that is 110M shares higher than the currently stated OS of 119,080,135 shares. The OS associated with the 229M share reported float was 595.400,675. And that OS tipped me to what I suspect will be a 5:1 forward stock split.
We previously had a former insider announce that he had accumulated a majority interest in the company of 70%. The stock rose 1,700% in the month of that announcement.
https://www.marketwatch.com/story/kalobios-short-sellers-facing-squeeze-as-ceo-shkreli-says-will-no-longer-lend-stock-2015-11-27
Things are a little different now. I think we own 100% of the shares we have issued. And we are not going to piss off HHS Secretary Becerra by price gouging, as Shkreli did for a therapeutic from his other biotech company. And Durrant didn't destroy the FDA on Tucker's show, as he could have. Instead, he referred to them as our "collaborative partner."
If we forward spilt, and merge with Baudax, that will likely result in a 6 month lockup of 238M shares of our 595M OS. If we then refuse to lend any stock...well, that's why I was glad to see that Schwab not only accepted my $100 sell price, they accepted the $200 sell price, as well. No way will I be able to hold off on making sells for less than $100, but at least I have those shares already allocated to $100 and $200 price levels.
I think the 110M excess shares in our market will have to be forward spilt to 550M, by the short sellers who have not made delivery of those shares. I'm hoping for one heck of a short squeeze.
You post is otherwise similar to one Preciouslife1 wrote. I want to research and comment on that in a reply to his post.
The key sentence, to me, regarding our success, is as follows.
"Humanigen and SAHMRI are assessing regulatory pathways that may enable early results to support a regulatory submission and potential provisional registration or approval by the Therapeutic Goods Administration in Australia.
https://medicalresearch.com/cancer-_-oncology/preach-m-trial-humanigen-study-evaluates-lenzilumab-and-azacitidine-for-cmml/
The reported results of that trial don't just support a favorable regulatory approval, they DEMAND it.
"Each parameter (blood monocytes, bone marrow blast percentage, platelet count, blood hemoglobin concentration, and spleen size) has exhibited a durable return to normal or near normal values, with statistical significance. Two of the ten participants have been in the trial for 18 months, the longest of any participants, and exhibit lasting improvement. No participants have relapsed. One participant is now a candidate for stem cell transplantation, which may lead to a potential cure in that patient."
Durrant has been telling us since last year that lenzilumab's performance in this trial could be the key that unlocks the door for us, and it's easy to see why he says that.
This isn't the first time I have seen clinical trial investigators express shock and joy at how quickly and effectively lenzilumab has caused patients to recover. I saw and heard the Mayo Clinic investigators express those same sentiments in our LIVE-AIR trial reviews.
A video of LIVE-AIR trial investigators Dr. Temsegen and Dr. Libertin, of Mayo Clinic, should be forwarded to The Therapeutic Goods Administration, as Dr. Thomas' comments regarding improved CMML results, echo the sentiments of the covid treatment doctors.
Last Quarter, it looks like we just had a 10-Q filing. And then, financial reporting sites have been copying and pasting management's comments from the Q on their sites.
POP/STOP
In regards to most recently adding to my position, I had said that my decision was influenced by our CMML trial co-investigator's excitement about the promising results of that trial, coming at the same time that Gilead scraps their trial, using magrolimab.
So, indication of a big leap forward for Humanigen, and a major defeat for Gilead.
Then, we hit a wall of our own, by the resignation of three Board Members, including the two independent members, which caused a Nasdaq non-conformance and delisting.
There was no justifiable reason for those immediate resignations. NONE. Hohnecker and Xie could have given notice of their intent to resign, rather than to breach their fiduciary duty to us shareholders and to Humanigen.
Hohnecker, in particular, should have fulfilled his fiduciary duty. It seems to me that he is another of what I consider as those "plug-and-play" senior leadership executives, like I considered Tim Morris. Look at Hohnecker's other current Board Memberships with Curis, Aravive, and Trishula. What kind of signal does this send to them?
https://www.linkedin.com/in/john-hohneker-407ab115?original_referer=https%3A%2F%2Fwww.google.com%2F
And Xie's role as Gracell's Chief Financial Officer is noteworthy.
https://www.linkedin.com/in/kevin-xie-a9a528?challengeSource=AgEN_ubVAfA1IgAAAYm_mlkEIhOLT47fdA4GQICdhZ389tXSJ4XuHqwmX3COf1c&challegeType=AgHUztjUXMOmgwAAAYm_mlkIQts9dT1mGNr7G8w1TT9197Zny47WrQk&memberId=AgH7rCqkNyRosgAAAYm_mlkLsxJBk7N291b-0p1CaXCve1E&recognizeDevice=AgGAhpLkqGJIVwAAAYm_mlkPChrIwnXVbPZYE9RAD4i5TkatiBWx&challengeId=AQFSOQhGXEg1GAAAAYm_zrz4EkyNpuX9325TSajpQhkTapTaiQtdNSRhoueZBtuYe80ci0vmpnmlsmwMLyh3tShxBtaEtPxTIw&submissionId=7c495c3d-0023-7817-053d-be9f31bc513c&challengeSource=AgHxp5zf9nIUIwAAAYm_z90QwNeFUUAapnS1CPSCAucOOeotOwaKFdyfOvlqHLI&challegeType=AgFjwhLpklM-GAAAAYm_z90Uk5TeFwsPw2BL8yOf9_BEDvxQjELu1_M&memberId=AgFR6BXfq5rq3AAAAYm_z90XDLOUfO4rZMVWPjvn1MuyGxs&recognizeDevice=AgENhoqvIb2VOwAAAYm_z90a2s9HW-XJ48yiTy-m9Qn7atAybpSO
"Gracell reports impressive data with one-day CAR-T for leukaemia
Takes fight to Novartis and Gilead"
Does our CAR-T represent a challenge to Gracell, as Gilead did?
https://www.pmlive.com/pharma_news/gracell_reports_impressive_data_with_one-day_car-t_for_leukaemia_1301432
These gentlemen could very well be of impeccable character, and I don't mean to impugn that. But they appear to have breached their fiduciary duty to me and all Humanigen shareholders, as well as to the company. I am extremely upset about the damage they have caused to all of us. I think it is understandable that I should want to know why they did this.
At these prices, I would love to be adding big time. But I can't. So I'm probably at the other end of the spectrum, coming in as one of the smallest shareholders.
We're seeing real signs of lenzilumab's efficacy revealed, so this is more than just a gamble.
Welcome to the room, poincianamike!
I was careless in my speech. I should have said I bumped-up my buy price, because I entered the buy at the Ask. (But I did get favorable slippage again).
I think we'll regain Nasdaq compliance with Baudax as a combined company. So maybe a ticker change, maybe not. But it's confusing, because I think a deal could still include PCI Pharma, too.
In and out of merger subs. Maybe maintaining 20% +18% +18% = 56% of HGEN, and 22% each of Baudax and PCI.
It will probably make the guys laugh to see how confused they have gotten me. But even more, I think we will somehow cash in on 110M FTD's, and work in a 5:1 forward stock split, too.
I bumped-up an open bid to add a few more shares today. It was mostly because Dr. Thomas, a co-investigator on the CMML trial, seemed even more enthusiastic in the 'Medscape' interview, than when the company first announced the results to the EHA Congress.
""I was very surprised that the RAS-mutant arm — so, patients that have KRAS, NRAS, or CBL mutations — are just responding beautifully to [lenzilumab], and that really has taken me by surprise,” Thomas said."
But the other reason I added was because Gilead had just the opposite reaction to their trial, using magrolimab. And that opens several doors for lenzilumab. As Durrant said, "These results may create the possibility for lenzilumab development in myelodysplastic leukemias."
I can only imagine the improved morale lenzilumab may bring to cancer health care providers, and patients, where "...treatment options for CMML patients are limited to blood transfusions, hydroxyurea, and supportive care alongside the current standard of care, which includes hypomethylating agents such as azacitidine and decitabine, which have limited response rates of 7% to 18%, with no proven increase in overall survival."
I will be even happier when covid health care providers and patients will also get access to lenz, even if it is for a new variant they haven't seen yet.
Can you tell me where management went wrong by achieving an 8-fold+ improvement in treatment outcomes for Black and African American covid patients? How did they fail in LIVE-AIR by achieving Hazard Ratios of between 2.5 - 3.4?
The CMML and aGvHD studies also used lenz, and we know that data is positive. I hope it results in regulatory approvals from the UK and Australia. Is that because management failed?
The attempted sabotage of our LIVE-AIR trial results by using sicker patients in the ACTIV-5 trial, even those on IMV, still showed improved treatment outcomes, comparable to the outcome achieved by Gohibic, for which they were given an EUA. Is that failed management?
Why is it so hard for you to understand that the reason we have lost $1.3B in market cap is because we threaten the $38B in covid revenue Pfizer is realizing?
The stark reality is, if this corruption is permitted to continue, our ICU's will be too overwhelmed and under-resourced to effectively save us. Stateside Chinese-owned biotech with bio-engineered mice to catch and carry covid? ICU utilization already increasing?
Direct your anger to where it rightly belongs, against the agencies charged with approving this life-saving therapeutic.
LOL !!
Please explain where I went wrong about the RATinG study being conducted across the UK for GvHD by the IMPACT stem cell transplant centers.
To PM, do you have any evidence that those comments were made, or are being made? I'd like to know, if you do.
No, Yooo. I wouldn't be as passionate as I am about this drug and the management of this company, if I was getting paid for my effort.
It should be about time for interim analyses for CMML and Acute GvHD, plus time for news as to whether we resubmitted our covid EUA application to the FDA, with a copy to the MHRA, based on ACTIV-5 supplemental safety and efficacy data, as well as comparable date to Gohibic for stage 6 patients.
So I hope we'll hear news about regulatory progress, as well as news related to our purchase of the Baudax shares, when our 10-Q is released in the next week, or two.
In the meantime, we'll just continue to communicate our thoughts and ideas, as we are now doing.
Word of the day: goad
"He refused to be goaded by their insults."
https://dictionary.cambridge.org/us/dictionary/english/goad
"GM-CSF Inhibitor Lenzilumab Shows Early Promise in CMML
Neil Osterweil
June 19, 2023...
Targeting GM-CSF
'I was very surprised that the RAS-mutant arm — so, patients that have KRAS, NRAS, or CBL mutations — are just responding beautifully to [lenzilumab], and that really has taken me by surprise,' said Daniel Thomas, MD, PhD, from the South Australian Health and Medical Research Institute, Adelaide, Australia, in an interview with Medscape Medical News...''
Thomas is a co-investigator of the ongoing phase 2/3 PREACH-M trial, which is testing a novel strategy of treating CMML with mutations in the RAS pathway with a combination of azacitidine and the investigational antibody lenzilumab, which is a targeted inhibitor of granulocyte-macrophage colony-stimulating factor (GM-CSF).
https://www.medscape.com/viewarticle/993375?form=fpf#vp_1
"In the open label, nonrandomized PREACH-M trial, 72 patients with CMML were enrolled and were assigned to receive 24 monthly cycles of therapy depending on mutational status...
Here at EHA 2023, the investigators reported available data on 10 patients enrolled in the lenzilumab arm and one enrolled in the azacitidine-sodium ascorbate arm.
Among patients in the lenzilumab arm there was a 5.1-fold decrease in monocyte counts (P = .03) and 2.4-fold decrease in blast counts (P = .04) at 12 months of follow-up.
In addition there was a trend toward increased platelet counts over baseline at 12 months, a significant increase in blood hemoglobin concentration (P = .024), a significant reduction in spleen size (P = .03) and a trend toward lower levels of the inflammatory marker C-reactive protein...
Thomas told Medscape that the investigators have been "pleasantly surprised” at how well patients tolerated the monoclonal antibody.
"We haven't had any infusion reactions, we haven't had any pulmonary alveolar proteinosis, we haven't had any fevers from the infusion, from the antibody,” he said."
https://www.medscape.com/viewarticle/993375?form=fpf#vp_2
Thanks to Stocktwits poster paivante69 for referencing the Medscape Medical News article.
"'Fairly shocking': Secret medical lab in California stored bioengineered mice laden with COVID
Thao Nguyen and Saleen Martin, USA TODAY
Updated Tue, August 1, 2023 at 10:36 AM CDT
A monthslong investigation into a rural California warehouse uncovered an illegal laboratory filled with infectious agents, medical waste and hundreds of mice bioengineered "to catch and carry the COVID-19 virus," according to Fresno County authorities.
Health and licensing said Monday that Prestige Biotech, a Chinese medical company registered in Nevada, was operating the unlicensed facility in Reedley, California..."
https://www.yahoo.com/news/fairly-shocking-secret-medical-lab-021812463.html
Good post, Yooo.
But chances are, that management has already bought every share the company has issued. So they know how valuable the company is.
And they know how to unlock that value which, in the short run, has nothing to do with our approval prospects, or projected revenue, or any of the standard business valuations.
They have to hold the brokerages accountable for the number of shares they have put into the market, and are charging clients margin loan interest to borrow. They have not done due diligence to verify the authenticity of those shares they loaned.
But, certain corporate actions, such as a stock split, a change in venue, or a merger, will FORCE an accounting of those shares. And I think we are seeing management take those necessary steps which will result in another short squeeze, propelled even higher, and with sustained price support, if the squeeze is supported with news of regulatory approval for a number of indications, including aGvHD, CMML, and covid.
I find use in Yooo's consistent negativity, to balance the perspective I offer, and give people a fuller view to consider than just my own.
A good example, and there are many, concerns our float. I believe there are 110M more shares in our market than the company has issued. I believe our float is 229M shares, because that number was associated with a reported OS of 595,400,675 shares. And that OS, means to me, that the company will declare a 5:1 forward stock split.
So I believe in those numbers, even with nothing now to substantiate them. But that float would also substantiate what I have been saying for years about our share structure, and how that could give a false impression about insider selling. That is a subject Yooo is absolutely sure about.
In addition, Yooo has often caused me to dig a little deeper on other issues we disagree about, and those have proven to be learning experiences for me, as I find justification for my position.
But you and others do not need to tolerate a room that permits personal attacks, even if they aren't always directed at you. And that needs to stop.
I think lenz retains an advantage over the E7 antibody method of action. Lenz works upstream of E7 by binding GM-CSF. Doing so would eliminate binding the spike proteins of the virus, because the virus would not progress to the point of needing to bind the spike proteins. In addition, it's not just the receptor cells that the virus can target. The virus also shows up in accessory cells, for example.
The lenz/vaccine/anti-viral cocktail will, in my opinion, be so successful, that we will stop the virus prophylactically. That will likely apply to stopping any virus, coronavirus or otherwise, that triggers a hyperactive immune response leading to Cytokine Release Syndrome (CRS).
Also, lenz has already clinically proven it's unmatched ability to prevent and treat cytokine storm in infected patients.
But an additional therapeutic solution, using a different technique to accomplish a similar effect, could be another arrow in the quiver of our therapeutic arsenal, and two is twice as good as one.
Please stop the personal attacks. Now.
Somehow, I thought sharing what I found, just the simple facts, with no expounding, might get through to you, without you finding it necessary to attack me.
LOL !!
I didn't just make up what I posted. It wasn't even a conclusion. I'm just sharing information that I have found.
HGEN.XA ?
So, an ETF with a phytomedical research and biopharmaceutical drug development company?
Targeting Cytokine release syndrome, or CRS...potential to reset the body’s immune system after triggering hyperinflammation. Post-exposure target population...
Interesting find, deserves study.
I wonder if Gilead wishes they had kept a non-exclusive right to use lenzilumab from Humanigen, instead of spending $4.9B on buying Forty Seven, and trying to use magrolimab in 30+ trials.
Maybe management would again license lenz to Gilead, non-exclusively, of course, and maybe for not much more than the $4.9B they spent buying Forty Seven, and maybe not to use for the indications we are pursuing. After all, what are frenemies for?
You posts are like smoke bombs, Yooo, an annoyance, but ultimately impact nothing. If you had tried to understand the obstacles management has to overcome on our, and on patients' behalf, maybe you could have learned something about the REAL issues here, such as OUR VERY LIVES, AND THOSE OF OUR LOVED ONES, are worth nothing compared to the greed of our competitors and regulators.
Ihub Developers. I absolutely HATE the Beta version of this site under development on Ihub. I hope you at least give users the option to continue to use the Classic current version.